Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 379820.0%.

  • Altimmune's EBITDA Margin rose 701400000.0% to 379820.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 420430.0%, marking a year-over-year decrease of 2218896200.0%. This contributed to the annual value of 475140.0% for FY2024, which is 4544301400.0% down from last year.
  • Altimmune's EBITDA Margin amounted to 379820.0% in Q3 2025, which was up 701400000.0% from 443640.0% recorded in Q2 2025.
  • Over the past 5 years, Altimmune's EBITDA Margin peaked at 728.99% during Q4 2021, and registered a low of 1182950.0% during Q3 2022.
  • Its 5-year average for EBITDA Margin is 273281.69%, with a median of 252837.5% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2022, then soared by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Altimmune's EBITDA Margin stood at 728.99% in 2021, then crashed by -11288bps to 83015.38% in 2022, then fell by -3bps to 85191.89% in 2023, then plummeted by -447bps to 466160.0% in 2024, then increased by 19bps to 379820.0% in 2025.
  • Its last three reported values are 379820.0% in Q3 2025, 443640.0% for Q2 2025, and 392100.0% during Q1 2025.